TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants

Clin Neurol Neurosurg. 2020 Sep:196:106059. doi: 10.1016/j.clineuro.2020.106059. Epub 2020 Jun 30.
No abstract available

Keywords: BRAF V600E mutation; Dabrafenib; MAPK/ERK; Panniculitis; Papillary TTF-1 positive posterior pituitary tumor; Pituitary spindle cell oncocytoma; Trametinib.

Publication types

  • Case Reports

MeSH terms

  • Adenoma, Oxyphilic / drug therapy
  • Adenoma, Oxyphilic / genetics
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Imidazoles / therapeutic use
  • Male
  • Middle Aged
  • Molecular Targeted Therapy / methods
  • Mutation
  • Oximes / therapeutic use
  • Pituitary Neoplasms / drug therapy*
  • Pituitary Neoplasms / genetics*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyridones / therapeutic use
  • Pyrimidinones / therapeutic use
  • Thyroid Nuclear Factor 1 / metabolism*

Substances

  • Antineoplastic Agents
  • Imidazoles
  • NKX2-1 protein, human
  • Oximes
  • Pyridones
  • Pyrimidinones
  • Thyroid Nuclear Factor 1
  • trametinib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • dabrafenib